The Nx Gen Sequencing Canavan Disease Test is a state-of-the-art genetic screening procedure available at DNA Labs UAE, designed to identify mutations in the ASPA gene, which are indicative of Canavan Disease. This highly advanced test leverages Next Generation Sequencing (NGS) technology to provide comprehensive insights into the genetic makeup of an individual, specifically targeting the variations linked to this severe neurological disorder. Canavan Disease is an autosomal recessive genetic disorder that affects the brain's ability to send and receive messages, leading to significant physical and cognitive disabilities from infancy.
Given its critical role in early detection and potential intervention strategies, the Nx Gen Sequencing Canavan Disease Test is a vital resource for families with a history of the condition or those exhibiting symptoms. The test is priced at 4680 AED, reflecting the sophisticated technology and expertise required to conduct this in-depth analysis. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test not only offers hope for affected families by facilitating early diagnosis but also contributes significantly to the ongoing research and understanding of Canavan Disease. By choosing DNA Labs UAE for this crucial testing, individuals are assured of accurate, reliable results and the highest standards of genetic analysis.
The "Nx Gen Sequencing Charcot-Marie-Tooth Disease and Sensory Neuropathies Test" is an advanced diagnostic tool offered by DNA Labs UAE, designed to identify genetic mutations associated with Charcot-Marie-Tooth disease and other related sensory neuropathies. Utilizing next-generation sequencing technology, this comprehensive test can analyze multiple genes known to be linked with these conditions, providing valuable insights into the genetic underpinnings of an individual's symptoms. With a cost of 4680 AED, the test aims to facilitate early diagnosis, guide treatment decisions, and offer prognostic information, ultimately contributing to improved patient care and management strategies for those affected by these debilitating neurological disorders.
The Nx Gen Sequencing Comprehensive Epilepsy Test is a cutting-edge diagnostic tool offered by DNA Labs UAE, designed to provide in-depth insights into the genetic underpinnings of epilepsy. This test employs next-generation sequencing (NGS) technology to analyze multiple genes known to be associated with various forms of epilepsy, enabling precise identification of genetic variations that may contribute to the condition. With a cost of 4680 AED, the test aims to offer a comprehensive genetic assessment for individuals experiencing epilepsy, aiding in the customization of treatment plans and management strategies based on the patient's unique genetic profile. By leveraging the power of NGS, DNA Labs UAE provides a valuable resource for patients and healthcare providers in the quest for more effective and personalized epilepsy care.
The "Nx Gen Sequencing Dementia Test" is a cutting-edge diagnostic tool available at DNA Labs UAE, designed to identify genetic markers associated with dementia. Utilizing Next Generation Sequencing (NGS) technology, this test comprehensively scans the genome for mutations and variants that are known to increase the risk of developing dementia, including Alzheimer's disease and other forms of cognitive decline. The test is priced at 4680 AED, reflecting the advanced technology and expertise required to perform the analysis. By providing a detailed genetic risk profile, the Nx Gen Sequencing Dementia Test offers individuals valuable insights into their genetic predisposition towards dementia, enabling early intervention strategies and personalized management plans to mitigate the impact of these conditions.
Next-Generation Sequencing (NGS) for Dravet's Syndrome and Early Infantile Epileptic Encephalopathy Test is a comprehensive diagnostic approach offered by DNA Labs UAE, aimed at identifying genetic mutations associated with Dravet's Syndrome and Early Infantile Epileptic Encephalopathy (EIEE). These conditions are severe forms of epilepsy that manifest in early childhood, leading to frequent seizures and, in many cases, developmental delays. NGS technology allows for the simultaneous examination of multiple genes to detect mutations that could be responsible for these disorders, providing a quicker and more efficient diagnosis compared to traditional methods.
The test is priced at 4680 AED, reflecting the advanced technology and expertise required to perform it. Conducting this test at DNA Labs UAE ensures that patients receive results that are accurate, reliable, and actionable, enabling healthcare providers to devise a tailored treatment plan based on the genetic makeup of the individual. This personalized approach to treatment can significantly improve the quality of life for patients suffering from these debilitating conditions.
The "Nx Gen Sequencing Duchenne and Becker Muscular Dystrophy Test" is a cutting-edge genetic screening offered by DNA Labs UAE, designed to accurately identify mutations associated with Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). These two conditions are among the most common forms of muscular dystrophy, characterized by progressive muscle weakness and degeneration. The test employs Next Generation Sequencing (NGS) technology, enabling a comprehensive analysis of the dystrophin gene (DMD) which is implicated in both disorders. This approach allows for the detection of a wide range of genetic mutations, including deletions, duplications, and point mutations, providing crucial information for diagnosis, prognosis, and guiding treatment strategies. The cost of the test is set at 4680 AED, reflecting the sophisticated technology and detailed analysis involved in delivering accurate and reliable results. Conducted at the state-of-the-art facilities of DNA Labs UAE, this test represents a significant advancement in the genetic diagnosis and management of Duchenne and Becker Muscular Dystrophy.
The "Nx Gen Sequencing Dystonia Test" is a cutting-edge diagnostic tool available at DNA Labs UAE, specifically designed to identify genetic mutations associated with dystonia. Dystonia is a movement disorder characterized by involuntary muscle contractions, leading to repetitive movements or abnormal postures. This test leverages Next-Generation Sequencing (NGS) technology to meticulously analyze the genetic markers linked to various forms of dystonia, providing a comprehensive understanding of the genetic underpinnings of the disorder.
By examining a broad spectrum of genes simultaneously, the Nx Gen Sequencing Dystonia Test offers a highly accurate and efficient approach to diagnosing dystonia, enabling tailored treatment strategies based on the individual's genetic profile. This personalized approach to diagnosis and treatment represents a significant advancement in the management of dystonia, offering hope to those affected by the condition.
The test is priced at 4680 AED and is conducted at DNA Labs UAE, a state-of-the-art facility renowned for its commitment to providing advanced genetic testing services. DNA Labs UAE employs a team of highly skilled professionals and utilizes the latest technology to ensure the highest standards of accuracy and reliability in genetic testing.
The Nx Gen Sequencing Episodic Ataxia Test is a comprehensive genetic test offered by DNA Labs UAE, designed to identify mutations in genes known to be associated with episodic ataxia, a rare neurological condition characterized by sudden attacks of ataxia (lack of muscle coordination) along with other symptoms such as vertigo, dizziness, and sometimes migraine. This condition is episodic in nature, meaning that symptoms come and go, leaving individuals symptom-free for periods of time.
The test employs next-generation sequencing (NGS) technology, a powerful method that allows for the rapid and accurate sequencing of large sections of DNA, making it possible to identify genetic variations that may contribute to episodic ataxia. By analyzing the patient's DNA, the test can pinpoint specific mutations in genes linked to this condition, providing valuable information for diagnosis, management, and treatment planning.
Offered at a cost of 4680 AED, the Nx Gen Sequencing Episodic Ataxia Test at DNA Labs UAE represents a significant advancement in the genetic diagnosis of episodic ataxia. It offers patients and their families the opportunity to gain a deeper understanding of their condition, potentially leading to more personalized and effective treatment strategies. The test is conducted in a state-of-the-art laboratory by a team of experienced professionals, ensuring high-quality and reliable results.
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare neurological disorder characterized by an abnormally large brain, white matter abnormalities, and the presence of fluid-filled cysts within the brain. This condition often presents in infancy or early childhood and can lead to a range of symptoms, including macrocephaly, ataxia, spasticity, and seizures, among others. The progression and severity of symptoms can vary significantly among affected individuals.
In the pursuit of accurate diagnosis and better understanding of MLC, Next Generation Sequencing (NGS) has emerged as a powerful tool. The "Nx Gen Sequencing Megalencephalic Leukoencephalopathy with Subcortical Cysts Test" is a specific diagnostic test offered by DNA Labs UAE, utilizing cutting-edge NGS technology to analyze the genetic mutations associated with MLC. This test focuses on identifying mutations in the MLC1 and HEPACAM genes, which have been linked to the condition. Identifying these mutations can confirm a diagnosis of MLC, provide valuable information for family planning, and contribute to the overall understanding of the disease.
The cost of the test is 4680 AED, reflecting the comprehensive nature of the analysis and the advanced technology employed. Conducted at DNA Labs UAE, a facility known for its state-of-the-art genetic testing services, this test represents a significant step forward in the diagnosis and study of megalencephalic leukoencephalopathy with subcortical cysts. Through such advanced diagnostics, patients and their families can gain access to more targeted support and management strategies for dealing with this challenging condition.
The Microarray 60K AFCVSCB Test, available at DNA Labs UAE, is a comprehensive genetic analysis procedure priced at 4680 AED. This cutting-edge test utilizes microarray technology to examine over 60,000 genetic markers across the human genome. It's designed to detect a wide range of genetic abnormalities and conditions, including but not limited to, chromosomal abnormalities, single nucleotide polymorphisms (SNPs), and copy number variations (CNVs). The "60K" in its name signifies the vast number of genetic markers it analyzes, offering a detailed and extensive genetic profile.
This test is particularly useful in clinical settings for genetic research, disease diagnosis, and personalized medicine. It can provide crucial information for understanding genetic disorders, predicting disease risks, and tailoring medical treatments to individual genetic profiles. Conducted in the state-of-the-art facilities of DNA Labs UAE, the test ensures accuracy, reliability, and confidentiality of results. Given its comprehensive nature and the advanced technology it employs, the cost of 4680 AED is reflective of the value it offers in terms of detailed genetic insights and potential implications for healthcare and disease management.
